# PALOMA-3 (NCT05388669)

> A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05388669
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Advanced or Metastatic Non-small Cell Lung Cancer
- Interventions: Lazertinib; Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF); Amivantamab Intravenous
- Enrollment: 418
- Primary outcome: For All Regions Other Than the European Union (EU) and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State
- Primary outcome: For EU and Any Applicable Region: Observed Serum Concentration (Ctrough) of Amivantamab
- Primary outcome: Area Under the Concentration (AUC) Time Curve of Amivantamab From Day 1 to Day 15 (AUC [Day 1-15]) of Cycle 2

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 68
- X threads: 66
- Podcasts: 55
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=paloma-3-nct05388669

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05388669", "email": "<work email>"}; the inbox owner confirms by the emailed link.